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Abstract
EphA2 is a receptor tyrosine kinase and is frequently
overexpressed in a wide array of advanced cancers. We
demonstrate in the current study that the EphA2 pro-
tein is restrictedly expressed in primary glioblastoma
multiforme and anaplastic astrocytoma tissues in com-
parison to normal brain tissues. To evaluate the possi-
bility of targeting EphA2 in glioma vaccine strategies,
we stimulated human leukocyte antigen (HLA) A2+
peripheral blood mononuclear cells (PBMCs) obtained
from healthy donors and glioma patients with auto-
logous dendritic cells (DCs) loaded with synthetic
EphA2883 – 891 peptide (TLADFDPRV), which has
previously been reported to induce interferon-; in HLA-
A2+ PBMCs. Stimulated PBMCs demonstrated antigen-
specific cytotoxic T lymphocyte (CTL) responses as
detected by specific lysis of T2 cells loaded with the
EphA2883 peptide as well as HLA-A2
+ glioma cells,
SNB19 and U251, that express EphA2. Furthermore,
in vivo immunization of HLA-A2 transgenic HHD mice
with the EphA2883–891 peptide resulted in the devel-
opment of an epitope-specific CTL response in spleno-
cytes, despite the fact that EphA2883 – 891 is an
autoantigen in these mice. Taken together, these data
suggest that EphA2883–891 may be an attractive anti-
gen epitope for molecularly targeted glioma vaccines.
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Introduction
Immunotherapy, particularly active vaccination, may be
developed as an effective and safe treatment modality for
malignant gliomas, which continue to have a poor progno-
sis, despite advances in surgical techniques and adju-
vant chemotherapy and radiotherapy [1]. Indeed, several
groups, including ours, have demonstrated the safety and
preliminary efficacy of whole glioma cell–based vaccine
approaches [2,3]. However, the use of autologous glioma
lysates or glioma cells as the antigen source may limit the
feasibility and safety of the approach due to the cumbersome
preparation procedures and theoretical concerns for inducing
autoimmune encephalitis [4]. Although the number of well-
defined glioma-specific cytotoxic T lymphocyte (CTL) epitopes
has been limited, our recent report describing a human leuko-
cyte antigen (HLA) A2–restricted CD8+ T-cell epitope derived
from the GAA interleukin-13 receptor a2-chain (IL-13Ra2)
demonstrates the feasibility of identifying such loci, particularly
when targeting a protein that is differentially expressed in
glioma cells versus normal tissues [5]. Given the marked
antigenic heterogeneity of gliomas, however, immunotherapy
with a single tumor-specific T-cell epitope might merely pro-
mote transient stabilization of disease, prior to the progression
of antigen loss variants [6]. We have therefore been dedicated
to broaden the list of available CTL epitopes for integration
into multiepitope-based vaccine strategies for glioma therapy.
EphA2 [7–9] is a member of the Eph family of receptor tyro-
sine kinases, comprised of two major classes (EphA and
EphB), which are distinguished by their specificities for ligands
(ephrin-A and ephrin-B, respectively) [7–9]. It has been
reported that EphA2 is frequently overexpressed and often
functionally dysregulated in advanced cancers, such as meta-
static lesions (reviewed in Ref. [10]). Because of the aggres-
sive and invasive nature of malignant gliomas, we hypothesized
that EphA2 might be expressed in this tumor entity and might
serve as an attractive target for glioma vaccines. Indeed,
T-cell immunoepitopes in EphA2 have been identified and
characterized as potential targets and surrogate markers for
cancer immunotherapy [11,12]. In the current study, we have
chosen to evaluate one of the HLA-A2–restricted epitopes,
EphA2883–891, because it has been noted to elicit relatively
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high level interferon (IFN) g responses in cancer patients,
in comparison to the other epitopes [12]. Here, we show
that EphA2 protein is expressed in human malignant glioma
and that stimulation with EphA2883–891 can induce tumor-
reactive CTLs in patient-derived HLA-A2+ peripheral blood
mononuclear cells (PBMCs) in vitro and by in vivo vaccina-
tion of mice transgenic for modified HLA-A2.1-b2 micro-
globulin single chain (HHD mice).
Materials and Methods
Cells and Cell Culture
The U251, SNB19, and A172 glioma cell lines [5] were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% FBS, 100 IU/ml penicillin, 100 mg/ml
streptomycin, and 10 mM L-glutamine (all reagents from Life
Technologies, Inc., Grand Island, NY).
PBMCs were obtained from glioma patients and healthy
donors under an Institutional Review Board–approved pro-
tocol. The HLA-A2 expression on the PBMCs was deter-
mined by flow cytometry as a double-positive staining with
monoclonal antibodies (mAbs) MA2.1 (against HLA-A2,
B17) and BB7.2 (against HLA-A2, Aw69) (both from ATCC,
Manassas, VA; www.atcc.org). The murine EL-4HHD [Dbxb2
microglobulin (b2M) null, and transgenic for modified HLA-
A2.1-b2 microglobulin single chain (HHD gene)] and control
EL-4S3-Rob cells (Dbxb2M null) were generous gifts from
Dr.Franc¸oisA. Lemonnier (Pasteur Institute, Paris, France) [13].
The HLA-A*0201–transfected transporter associated with
antigen processing (TAP)–deficient T2 cell lines [5], EL-
4HHD and EL-4S3-Rob cells, were maintained in RPMI
1640 medium (Life Technologies, Inc.) supplemented with
10% fetal bovine serum (FBS), 100 IU/ml penicillin, 100 mg/ml
streptomycin, and 10 mM L-glutamine (all reagents from Life
Technologies, Inc.).
Peptides
The synthetic EphA2883–891 (TLADFDPRV) and control
MART-127–35 (AAGIGILTV) were synthesized by FMOC
chemistry in the University of Pittsburgh Cancer Institute
(UPCI) Peptide Synthesis Facility, and were >95% pure as in-
dicated by analytic high-performance liquid chromatography
and mass spectrometric analysis performed by the University
of Pittsburgh Cancer Institute’s Protein Sequencing Facility.
Peptides were dissolved in phosphate-buffered saline (PBS)/
10% DMSO at a concentration of 2 mg/ml and stored at
20jC until use.
Western Blot
Tumor cells (5–10  106) were analyzed for EphA2
expression through Western blot analysis as described
previously [12], with slight modifications. Cell lines were col-
lected by scraping in PBS and were pelleted before lysis in
a buffer containing the protease inhibitors, phenylmethyl-
sulfonyl fluoride (100 mg/ml), aprotinin (1 mg/ml), and leupep-
tin (1 mg/ml) (all these reagents from Sigma, St. Louis, MO).
Lysate protein concentrations were determined using a Bio-
Rad protein assay kit (Bio-Rad, Hercules, CA). Protein
samples were denatured in gel-loading buffer at 99jC for
5 min. Equal amounts of proteins (40 mg) were applied to each
well and electrophoresed on 7% polyacrylamide gel. Proteins
were transferred to nitrocellulose membranes (Bio-Rad) and
blocked with 5% low-fat skim milk for 1 hour at room tem-
perature. Blots were incubated with the antihuman EphA2
polyclonal antibody (c-20; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) or actin (ACTN05; NeoMarkers, Fremont,
CA), followed by species-specific secondary antibodies (mouse
and rabbit, respectively; Santa Cruz Biotechnology, Inc.). Blots
were imaged on a Kodak X-Omat Blue XB-1 film (NEN Life
Science Products, Boston, MA) using an enhanced chemilu-
minescence detection system (Amersham, Piscataway, NJ).
Immunohistochemistry for EphA2 in Glioma Tissue
Glioma specimens were obtained surgically under an In-
stitutional Review Board–approved protocol and paraffin-
embedded. Normal brain sections were obtained from the
Human Brain Tissue Bank, Evelyn F. and William L. McKnight
Brain Institute of the University of Florida. Eight-micrometer
sections were deparaffinized, rehydrated, and subjected to
antigen retrieval by electric pressure cooker (DC2000; Bio-
care Medical, Walnut Creek, CA) in DakoCytomation Target
Retrieval Solution (DakoCytomation, Glostrup, Denmark).
Endogenous peroxidase was blocked with 3% H2O2 in
PBS. Anti-EphA2 mAb (Ab 208, mIgG1; MedImmune, Inc.,
Gaithersburg, MD) or isotype-matched control mAb was
incubated on sections for 2 hours at room temperature. After
PBS washing, sections were incubated with biotinylated
secondary antibody (Vector Laboratories, Burlingame, CA)
for 20 minutes at room temperature, then incubated with
avidin–biotin complex horseradish peroxidase (Vectastatin
ABC kits; Vector Laboratories) for 10 minutes, developed
with a Nova Red substrate kit (Vector Laboratories), then
nuclei were counterstained with hematoxylin. The expres-
sion intensity of EphA2 immunostaining (negative, lightly
diffuse, moderately diffuse, focally moderately diffuse, or
strongly diffuse) was evaluated independently with a micro-
scope under 20 to 40 magnification.
In Vitro Induction of CTL with the EphA2883–891 Peptide
Induction of CTL responses in HLA-A2+ PBMCs against
HLA-A2–binding peptides was evaluated with a previously
described method by us [5], with slight modifications. Briefly,
autologous dendritic cells (DCs) (2 105 per well), which were
preincubated with each peptide (10 mg/ml) for 2 hours, were
cocultured with 2  106 CD8+ Tcells in a final volume of 2 ml
(each well of 24-well plates) of AIM-V media supplemented
with 10%humanserum (both reagents fromLife Technologies,
Inc.) and 20 U/ml human rhIL-2 (R&D Systems, Minneapolis,
MN). On day 7, lymphocytes were restimulated with autolo-
gous DCs pulsed with the peptide, and the stimulated T cells
were analyzed for their specific CTL activity on day 14 by
standard 51Cr release assays. For the cold target (CT) inhibi-
tion assays, 51Cr-labeled SNB19 cells (1 103 cells/well) and
cold T2 cells (1  104 cells/well), pulsed with or without
EphA2883–891, were incubated with the effector cells.
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Vaccination of HHD Mice with EphA2883–891 Peptide
HHD mice received (on days 0 and 7) subcutaneous
(s.c.) injections of 100 mg of EphA2883–891 peptide emulsified
in incomplete Freund’s adjuvant (IFA) in the presence of
140 mg of I-Ab–restricted HBVcore128 (TPPAYRPPNAPIL)
T-helper epitope, which stimulates a CD4+ helper T-cell re-
sponse [14]. Control animals received IFA containing HBV
helper peptide only. On day 14, the animals were sacrificed,
and 5  107 splenocytes (SPCs) were stimulated in vitro
with the same peptide that was used for in vivo stimula-
tion (10 mM). On day 6 of culture, the bulk populations were
tested for specific cytotoxicity against the EL4-HHD cells
pulsed with EphA2883–891, and control unpulsed EL4-HHD
or EL4S3-Rob cells. All animal experiments were performed
under Institutional Animal Care and Use Committee (IACUC)–
approved protocols.
Statistical Analyses
Statistical differences between groups were assessed
using aStudent’s t test for two sampleswith unequal variances.
Statistical significance was determined at the < .05 level.
Results
Expression of EphA2 Protein in Human Glioma Tissues
First, we evaluated the EphA2 expression in surgically
resected human glioma tissues. Immunohistochemical analy-
ses of paraffin-embedded specimens using anti-EphA2 mAb
(Ab208 mIgG1) demonstrated a partly membranous, partly
diffuse cytoplasmic staining pattern in EphA2+ cells (Figure 1).
In comparison to the normal brain specimens (Figure 1D),
which exhibited a negative or minimal, lightly diffuse pattern
of EphA2 staining, high-grade gliomas, including 10 anaplas-
tic astrocytoma (AA) and 9 glioblastoma multiforme (GBM),
demonstrated variable levels of generally diffuse EphA2
expression in all cases (Figure 1, A–C and Table 1). In ad-
dition, one gemistocytic astrocytoma and one gliomatosis
cerebri case, as well as one of two grade II astrocytoma (dif-
fuse fibrillary astrocytoma) cases, demonstrated a diffuse
EphA2 expression. Taken together, EphA2 appeared to be
expressed in all malignant gliomas examined with a variety of
intensity levels. However, the tumor grade did not appear to
correlate with the staining intensity levels.
Induction of EphA2883–891 Peptide–Specific CTL Lines
We have previously reported EphA2-derived T-cell epi-
topes that are able to induce IFN-g responses in CD8+ cells
from HLA-A2+ patients [12]. Among five HLA-A2–binding
peptides described in this reference study, EphA2883–891
produced higher IFN-g induction levels than the others
[12]. We therefore chose to examine this peptide for its ability
to induce CTL responses in CD8+ PBMCs derived from
HLA-A2+ glioma patients. Human glioma cell lines SNB19
(HLA-A2+), U251 (HLA-A2+), and A172 (HLA-A2), but not
normal PBLs, expressed a high level of EphA2 proteins
based on Western blot analysis (Figure 2), and thus were
used as target cells in parallel with peptide-pulsed T2 cells.
Figure 1. EphA2 expression in GBM tissues. Paraffin-embedded GBM (A–C) or normal brain (D) sections were examined for EphA2 expression using anti –
EphA2-specific antibody (Ab208; MedImmune, Inc.) as described in Materials and Methods section. The case in (A) was scored as strongly diffuse, and cases in
(B) and (C) were scored as moderately diffuse in Table 1 (original magnification, 20).
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Figure 3 depicts specific CTL reactivities in one healthy
donor (Figure 3A) and one representative glioma patient
(Figure 3, B–D) following two cycles of stimulation with
autologous DCs loaded with EphA2883–891. Responder T cells
efficiently lysed T2 target cells pulsed with the EphA2883–891
peptide, whereas only low background lysis was observed
inthe absence of the peptide or T2 cells loaded with irrelevant
control MART-127–35 (Figure 3, A and B). These results
demonstrated that the CTL line induced with EphA2883–891
recognized the relevant antigen peptide specifically and was
able to lyse cells presenting the peptide.
More importantly, we examined whether the patient-
derived responder cells were able to recognize and lyse
HLA-A2+ human glioma cells that endogenously expressed
and presented EphA2883–891 epitope. The standard
51Cr
release assays revealed the HLA-A2+ SNB19 and cell
U251 lines were highly susceptible to lysis by the CTL line,
whereas the HLA-A2 A172 cells were not susceptible to
lysis by the responder cells, suggesting that the CTL reac-
tion is HLA-A2–restricted (Figure 3C). To determine the
specificity of the lytic activity, CT competition experiments
were performed by addition of nonradiolabeled T2 cells
pulsed with EphA2883–891 peptide in the
51Cr release assay
(Figure 3D). The lytic activity of the CTL line against these
glioma cell lines was almost completely inhibited by the ad-
dition of the cold T2 pulsed with EphA2883–891 peptide, but
not by nonpulsed cold T2 cells, demonstrating that the lytic
ability was specific for the epitope EphA2883–891. These data
indicated that HLA-A2+ donor-derived PBMCs stimulated
with EphA2883–891 peptide were capable of recognizing and
lysing HLA-A2+ glioma cell lines that endogenously ex-
pressed EphA2, suggesting that the EphA2883–891 peptide
might be useful for inducing antiglioma immunoreactivity.
Vaccination of HHD Mice with EphA2883–891 Peptide–
Induced Antigen-Specific CTL Response
To evaluate the immunogenic potential of EphA2883 pep-
tide in vivo, HHD mice were immunized with EphA2883–891
peptide. As the amino acid sequence for human EphA2883–891
is completely identical to the corresponding portion in mouse
(m) EphA2 (NCBI accession nos. AAH37166 and NP_034269,
respectively), vaccination with EphA2883–891 in this mouse
model may serve as an attractive and clinically relevant model
in the light of overcoming potential partial tolerance against
an autoantigen epitope. The EphA2883–891–specific CTL ac-
tivity in the SPCs from the immunized HHD mice was ex-
amined with EL-4-HHD cells pulsed with EphA2883–891 by
standard 51Cr release assays. As EL-4HHD cells express
only a modest level of EphA2 protein (Figure 2), nonpulsed
EL-4-HHD cells were used as controls. As depicted in Figure 4,
the responder bulk SPCs demonstrated a significantly higher
lytic activity against EphA2883–891– loaded EL-4HHD cells
in comparison to nonpulsed EL-4-HHD cells, supporting the
peptide-specific nature of the effector cell response. Inter-
estingly, nonpulsed EL-4-HHD cells demonstrated slightly
higher susceptibility to the SPCs than EL-4 S3Rob cells that
do not express the HHD gene [P < .05 at all effector-to-
target ratios (E/T ratios) higher than 10], suggesting the
EphA2883–891 epitope derived from endogenously expressed
EphA2, albeit low levels, may still be presented in the context
of HHD. Control animals that received mock immunizations
demonstrated only background CTL reactivities under the
same conditions (data not shown). These data suggest
EphA2883–891 epitope may serve as an efficient vaccine an-
tigen in vivo.
Discussion
The most significant findings in the present study are that
human malignant gliomas express EphA2 protein and that
EphA2883–891 epitope can induce an antigen-specific, anti-
glioma CTL response in HLA-A2+ patient–derived PBMCs.
These findings strongly support the rationale for targeting
EphA2 in peptide-based vaccine trials for patients with AA
and GBM.
Our immunohistochemical analyses demonstrated vari-
able levels of EphA2 expression in all high-grade (grade III or
IV) gliomas examined. However, unlike many other cancer
types in which EphA2 expression levels predict malignant
behaviors of cancers [10,15], expression levels in gliomas
did not correlate with the tumor grade, as both AA and GBM
cases had variable expression levels and one of two grade II
astrocytoma (diffuse fibrillary astrocytoma) cases expressed
a high level of EphA2. This may be due to the fact that both
AA and GBM are highly malignant tumors with aggressive
invasiveness into the surrounding normal brain tissue. Fur-
ther evaluation with additional low-grade astrocytoma cases
and other gliomas, such as ependymoma, is warranted.
Nevertheless, EphA2 appeared to be expressed widely in
Table 1. Tumor Grades and EphA2 Expression Levels.
Histologic Diagnosis
and Grade
Staining Evaluation
of Slide
Number of
Cases
Astrocytoma grade II Negative 1
(diffuse fibrillary astrocytoma) Strongly diffuse 1
AA Lightly diffuse 5
Moderately diffuse 3
Strongly diffuse 2
GBM Lightly diffuse 4
Moderately diffuse 3
Strongly diffuse 2
Gemistocytic astrocytoma Strongly diffuse 1
Gliomatosis cerebri Moderately diffuse,
diffusely infiltrating tumor only
1
Figure 2. Human glioma cell lines express the EphA2 protein at high levels.
Expression of EphA2 protein was analyzed in three human glioma cell lines
(SNB19, U251, and A172), healthy donor –derived PBLs, and two mouse
lymphoma cell lines (EL-4 and EL-4-HHD) by Western blot analysis using
anti-EphA2 polyclonal antibody (C-20) and anti –pan-actin mAb (ACTN05) as
internal controls.
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high-grade gliomas and is relatively restricted in tumor
tissues as normal brain samples examined had little or no
EphA2 expression. In our previous study with amousemodel
[16], EphA2 expression was not detected in the mouse brain
based on Western blot analysis, supporting the finding that
the EphA2 expression in the central nervous system is
restricted to gliomas.
We also demonstrated that EphA2883–891 peptide induced
a specific CTL response in HLA-A2+ donor–derived PBMCs
in vitro. It was noteworthy that the levels of CTL activity
observed in patient-derived PBMCs were as high as those ob-
served inhealthydonor–derivedPBMCs inmostcases,unless
the donor patient suffered from clinical lymphopenia (defined
as anabsolute lymphocyte count < 800 ml1) due to concurrent
chemotherapy and/or radiotherapy.We are currently optimiz-
ing the conditions for the fluorescence-conjugated tetramer
for EphA2883–891, which will allow us to evaluate the fre-
quency of EphA2883–891, recognizing CD8
+ T cells in glioma
patients undergoing our perspective vaccine trials.
It has been well recognized that the CTL repertoire
against high-affinity epitopes is often partially tolerized [13],
and this mechanism may explain the limited levels of CTL
responses against a majority of tumor-associated autoanti-
gens. However, our data employing HHD mice indicated that
vaccinations with IFA containing the EphA2883–891 peptide
effectively mounted an antigen-specific CTL response that
was demonstrated not only against peptide-loaded EL-4-HHD
cells but also against EL-4-HHD cells that endogenously
express EphA2, suggesting that the EphA2883–891 peptide is
capable of inducing a specific CTL response in vivo with the
assistance of effective adjuvants.
There is a theoretical possibility that vaccinations of
patients with EphA2-derived peptides can induce autoimmune
reactions because of their expression in the normal lung,
spleen, and liver [16]. However, EphA2 is not expressed in
mouse brain [16], and we have not observed any inflammatory
pathology in normal organs in HHD mice following vaccina-
tions with the EphA2883–891 (data not shown). This novel CTL
epitope may therefore serve as an attractive component of
peptide-based vaccines to treat patients with high-grade
glioma [3,17] and as a surrogate marker of T-cell immune
responses in patients before and after immunotherapy.
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Figure 3. Stimulation of HLA-A2+ donor –derived PBMCs with EphA2883 – 891 – induced antigen-specific CTL responses. (A and B) T-cell lines generated from a
healthy donor (A) or patient 1 (B) by stimulation with EphA2883 – 891 peptide were tested for their ability to lyse
51Cr-labeled T2 pulsed with EphA2883 – 891 (E) or
irrelevant MART-127 – 35 (AAGIGILTV) (z) or without peptides (n). P < .05 at all E/T ratios for EphA2883 – 891–pulsed T2 versus other groups. (C) T-cell lines
generated from patient 2 with EphA2883 – 891 peptide were incubated for 4 hours with
51Cr-labeled human glioma cell lines SNB19 (.; HLA-A2+, EphA2+), U251 (n;
HLA-A2+, EphA2+), and A172 (z; HLA-A2, EphA2+) at the indicated E/T ratios for evaluation of specific lytic ability. P < .05 at all E/T ratios for A172 vs U251 or
SNB19. For the CT inhibition assay (D), 51Cr-labeled tumor target cells (5  103 cells) and cold T2 cells pulsed with (o) or without (E) EphA2883 – 891 peptide were
incubated with CTLs from patient 3. P < .05 at E/T ratios 50 and 100 for peptide-pulsed T2 (cold inhibition) versus other groups. These data are representative of at
least three independent experiments with each of the three different donors. Bars = SD.
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